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ABSTRACT

High prevalence rates of depression have been well documented in patients with chronic
kidney disease (Egede, 2007; U.S. Renal Data System, 2013). Furthermore, depression seems to
play a major role in the mortality and morbidity rates of this population (Kellerman, Christensen,
Baldwin, & Lawton, 2010; U.S. Renal Data System, 2013). Therefore this study aimed to
discover factors that may influence depression in this population. Ten end-stage renal disease
(ESRD) patients’ depression scores were examined in relation to various sociodemographic
measures. High depression scores had a significantly negative relationship with social
functioning, overall quality of life, and age. A combined model of social functioning, sleep
quality, and age provides a stronger prediction than any variable alone. Results suggest that
targeting social functioning, sleep quality, and age should be the focus of future studies
examining interventions of these factors as augmentations to current pharmacological treatments
of depression in ESRD populations.
Keywords: End-Stage Renal Disease, Depression
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CHAPTER I
INTRODUCTION

Depression affects many people around the world regardless of age, health, gender, and
ethnicity. However, research has shown that those with chronic diseases such as end-stage renal
disease (ESRD) show higher rates of depression and are more prone to depressive symptoms
compared to the general public (Egede, 2007; U.S. National Library of Medicine, 2014; U.S.
Renal Data System, 2013). Furthermore, within the ESRD population, it has been shown that
higher levels of depression may be predictive of higher mortality rates (Kellerman et al., 2010;
U.S. Renal Data System, 2013). These two findings point to the increased need to reduce
depression in those with chronic diseases. The current study aims to provide more information
about the relationship of depression with other individual factors in kidney disease patients. The
ultimate goal is to use this information to develop better intervention strategies that can lower the
depression levels of those with chronic diseases, which may lead to lower mortality and improve
the quality of life in this population.

Background
End-Stage Renal Disease (ESRD) is known as the fifth and final stage of Chronic Kidney
Disease (CKD), and can be characterized by the individual requiring either a kidney transplant or
some form of dialysis in order to live (U.S. National Library of Medicine, 2014). In 2011 it was
estimated that nearly 400,000 people suffer from ESRD in the United States alone (U.S. Renal
1

Data System, 2013). Many times ESRD results from long-term kidney problems due to diabetes
or hypertension, with diabetes accounting for one-third and hypertension accounting for onefourth of the ESRD incidents in 2011 (U.S. Renal Data System, 2013). Additionally, ESRD
patients often suffer from a variety of comorbidities, including cardiovascular disease,
depression, and malnutrition, with depression being one of the most prevalent in the population.
Multiple studies estimate the prevalence of depression to be between 20% and 25% in ESRD
patients, as compared to a 2% to 4% prevalence in the United States population (Chiang, Livneh,
Yen, Li, & Tsai, 2013; Egede, 2007; Kimmel, Cukor, Cohen, & Peterson, 2007). This high
prevalence of depression within the ESRD population warrants even more attention due to the
link between depression and increased mortality rates in those with ESRD. Several studies show
significant positive correlations between depression and mortality in the ESRD population,
including some results that indicate depression is associated with nearly a 22% increase in
mortality for depressed patients compared to those who do not suffer from depressive symptoms
(Kellerman et al., 2010; van Dijk et al., 2012; Ver Halen, Cukor, Constantiner, & Kimmel,
2012).

Objectives of the Study
The literature and statistics discussed in the previous section provide the rationale for
setting the focus of the current study on depression and determining what factors play a role in
the depression symptoms of this particular population. The main goal of the study is to provide
more information on the roles of social functioning, quality of life, sleep quality, and length of
time on dialysis in ESRD patients, to determine which factors may have the strongest
relationship with depression in this population. With this information it is hoped that additional
2

treatments or care-taking strategies can be implemented that would promote the reduction of
depression symptoms in ESRD patients, which may subsequently lower the mortality rate and
increase quality of life. Furthermore, prolonging the lifespan of this population is crucial as it
gives these patients more time to receive a transplant, which is well documented to have a
tremendous effect on quality of life and life expectancy compared to dialysis patients (Álvares,
Cesar, de Assis Acurcio, Andrade, & Cherchiglia, 2012; U.S. National Library of Medicine,
2014; U.S. Renal Data System, 2013).
The present study looks at perceived social functioning, quality of life, sleep quality, and
age – factors studied previously in the literature. It adds to this literature by verifying previous
findings, clarifying the literature on the effects of length of time on dialysis, while also
contributing unique information by examining the effect of these factors combined. The
following literature review examines each of the factors included in this study in detail, to
understand what has previously been done and what is still missing from the literature.
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CHAPTER II
LITERATURE REVIEW

Review of Related Studies
Social Functioning
Past research on factors that influence depression in ESRD patients has focused primarily
on psychosocial factors such as perceived social support. It is important to notice the focus of
perceived support, as the depression symptoms observed are often a result of how much support
the patient perceives, rather than the amount of support an objective measure might suggest.
Additionally, it is also important to note that social support is a broad term used to encompass a
range of social constructs. Many have argued that the term social support is not specific enough
to be a reliable research measure, because it is a measure that includes too many factors that
should be studied individually (Barrera, 1986; Cohen & McKay, 1984; Cohen & Wills, 1985;
Heller, 1979). The present study heeds to these suggestions by studying a specific aspect of
support (social functioning) to determine how it may be related to depression symptoms in
ESRD patients, compared to common literature studies focusing on social support as a generic
term.
In one of the first studies examining social support as defined generically in ESRD
patients, Christensen, Turner, Slaughter, and Holman (1989), grouped 57 ESRD patients into a
high or low group based on their reported support levels. Christensen et al. (1989) found that
those in the high social support group showed significantly lower depression and higher
4

psychological well-being levels compared to those in the low social support group. An additional
study by Christensen and colleagues grouped subjects into a high support group and low support
group, finding the group with low perceived support had a mortality rate of 58%, nearly threetimes higher than those with high perceived support with a rate of 18% (Christensen, Wiebe,
Smith, & Turner, 1994). Several others have also documented the impact of perceived social
support on depression. Chan and colleagues (2011) conducted a meta-analysis of 57 studies to
examine the role of the most commonly studied psychosocial factors, such as social support
(subjective and objective), stress, and personality attributes, in chronic dialysis patients to assess
which factors had the most significant impact on depression levels. Results of this meta-analysis
showed perceived social support, along with stress, to have significantly higher effect sizes than
all other factors, .33 and .37 respectively, in a pooled sample that included nearly 6,000 subjects
(Chan et al., 2011).
In addition to the ESRD population, more recent research has shown the relation between
social support and depression to hold steady in otherwise healthy populations as well. Wang and
Zhao (2012) studied the relationship between depression and social support by comparing a
group of older adults (ages 60-80) diagnosed with major depressive disorder to a group of nondepressed older adults in the same age group. Results showed that the depressed group showed
significantly less perceived social support than the non-depressed group. Similar results were
found in a study of depressed young adults (ages 16-21) with no comorbidities, where perceived
social support was associated with lower levels of stress and depression (Raffaelli et al., 2013).
In summary, perceived social support plays an important role in depression levels of
ESRD patients. It is not yet known whether specific subtypes of support, such as social
functioning are equally important in depression. As Barrera (1986) suggests, the use of more
5

specific measures of social support should provide a more accurate view of the relation between
support and depression.

Health Related Quality of Life
Health related quality of life refers to a combination of both physical and mental health
factors (Ware & Sherbourne, 1992), and is another factor that is thoroughly discussed in the
literature of ESRD patients. Health related quality of life is often measured by subjective report,
similar to perceived social support, as it is often the perceived physical or mental health that is of
interest when studying depression. While a great amount of literature focuses on perceived social
support, a considerable amount of research has also explored the overall health related quality of
life of ESRD patients. In addition, a recent study suggests that health related quality of life is
becoming an even more important factor to consider for today’s ESRD patients as medical
advances have helped increase the life expectancy of patients on dialysis (Glover, Banks, Carson,
Martin, & Duffy, 2011).
With an increase in life expectancy, the quality of life in the ESRD population must be
monitored more closely. To better monitor health related quality of life, it is crucial to
understand what factors influence it in the ESRD population. In their study of 49 ESRD patients,
Steele et al. (1996) found that depression was strongly correlated to health related quality of life
scores, as measured by the Patient-Assessed Quality of Life index (PAQoL), and advised that the
link between the two should be considered carefully when devising caretaking plans for this
population. More recent research has further accentuated the relationship between depression and
health related quality of life. In 2005, a study of 194 dialysis patients showed depression was
correlated more highly with health related quality of life than any other psychosocial factor
6

included in the study (Vázquez et al., 2005). Perales-Montilla, Garcia-Leon, and Reyes-del Paso
(2012) also found depression to be a significant predictor of low health related quality of life in a
sample of ESRD patients. These results reflect the need to consider health related quality of life
as a factor that may influence depression in the current study, to determine if it should be a target
for caretaking strategies of those suffering from both depression and ESRD.

Sleep Quality
Like poor health related quality of life, sleep disturbances are also frequently reported
among ESRD patients (Brekke et al., 2013). Estimates from recent literature report between 65%
and 75% of ESRD patients suffer from “poor sleep” as subjectively rated using the Pittsburgh
Sleep Quality Index (PSQI), a commonly used measure of sleep quality in the ESRD literature
(Brekke et al., 2013; Iliescu et al., 2003; Kusleikaite, Bumblyte, Razukeviciene, Sedlickaite, &
Rinkunas, 2005). The high prevalence of sleep disturbances mark sleep quality as another target
for inspection to determine if it has a role in predicting depression scores. An assortment of
recent studies on ESRD patients’ sleep quality conclude that it does. Brekke et al. (2013) studied
301 dialysis patients to determine the association between sleep quality, as measured by the
PSQI, and depression. The PSQI measure characterizes “poor sleep” as a score of greater than 5
out of 21 on a range of questions about patients’ sleep quality in the last month. The results
showed “poor sleep” was significantly related to depression, and that “poor sleepers” scored
significantly lower on mental components of health related quality of life measures than good
sleepers. In another study, self-reported cases of insomnia were found to be associated with
higher depression levels (Paparrigopoulos, Theleritis, Tzavara, & Papadaki, 2009). Additionally,
poor sleep quality may lead to more problems and higher depression in otherwise healthy adults
7

as well. In a large sample of over 3,000, “poor sleepers” assessed by the PSQI showed an
increase in comorbidities (60%) compared to “good sleepers” (38%), while the proportion of
depression increased significantly as sleep quality worsened (Hayashino et al., 2010).
Collectively, this literature provides another possible link with depression that can be assessed
through the present study, to determine if sleep quality should be another focus when considering
ways to lower depression levels in the ESRD population.

Length of Time on Dialysis
Unlike some of the other factors discussed thus far, length of time on dialysis is an
important demographic factor in this population that is not often examined or discussed in the
literature regarding the ESRD population. Early research reported a significant relationship
between length of time on dialysis and self-reported depression (Kutner, Fair, & Kutner, 1985),
and more recently, a study found a significant difference in the perceived consequences of
treatment in participants with varying lengths of time on dialysis (Jansen et al., 2013). In this
study, perceived consequences of treatment were assessed by the Treatment Effects
Questionnaire which asks the participant to answer questions about the impact of side-effects due
to treatment, how much their life revolves around the treatment, and whether the treatment
“keeps them from enjoying themselves.” Results of this study showed that the perceived
treatment consequences were significantly more negative for patients who were on dialysis for
longer lengths of time (Jansen et al., 2013). These studies provide some evidence that length of
time on dialysis may play a role in depression levels of ESRD patients. However, despite these
findings the topic is still greatly understudied and needs to be further established in the literature.

8

Although evidence of a direct association between time on dialysis and depression scores
is substantially understudied in the ESRD population, some studies have shown associations
between time on dialysis and other factors that may be indirectly related to depression levels,
such as adherence to treatment (Hudson, Fielding, Jones, & McKendrick, 1987). In contrast to
length of time on dialysis, the association between adherence to medical treatment and
depression in ESRD and other chronic disease populations is well documented in the literature
(Bolkan et al., 2013; Sacco et al., 2007; Theofilou, 2013; Zhang et al., 2013). Collectively these
findings provide evidence that length of time on dialysis could play an indirect role in depression
levels.

Age
Age, like gender, is a common demographic collected in research that it is included in
nearly every study regardless of the topic. The same is true for ESRD and depression studies;
however, the results of the literature in the particular area of depression in ESRD populations
may not be as transparently logical compared to other studies examining age effects. Studies that
include age effects in their studies on depression in ESRD populations have found some
interesting results as to which age group is more depressed. A study by Laudanski, Nowak, and
Niemczyk (2013) examined quality of life, depression, and coping strategies of ESRD patients to
determine if there were any age related differences in the way younger (mean age = 47.1) and
older adults (mean age = 68.3) cope with their disease. It was found that while both groups
showed higher levels of depression than a healthy, age-matched control group, younger ESRD
patients showed higher levels of depression, and more frequently used emotional preoccupation
strategies to cope than the older patient group. Additionally, younger patients made significantly
9

more complaints about sleep disturbances, which correlate strongly with depression levels, as
reviewed earlier.
Additional studies have found similar results in ESRD populations, in which age is
negatively correlated with depression and other measures of mental health (Chilcot et al., 2011;
Griva et al., 2014). With these studies in mind, it is of interest to look more closely at age and its
relationship with depression.

The Present Study
Many of the factors included in the present study have been shown in the literature to
have either a direct, or possibly indirect, relationship with depression, providing the logic for
including each of them in exploring some of the factors that might help better predict
experiences of depression in ESRD patients. However, in the same way each of the factors is
connected, they also each provide a unique target for intervention when it comes to the care of
this population because they each examine the issue of depression from a different aspect.
Therefore, the present study was designed to determine which of the factors included (social
functioning, health related quality of life, sleep quality, length of time on dialysis, and age) or
which combinations of these factors best predict levels of depression in ESRD patients.

Hypotheses
Based on the previous review of the literature, the following hypotheses were explored in
the present study. Depression scores in the present study were assessed using the Center for
Epidemiologic Studies Depression Scale, Revised Version (CESD-R), which is detailed in the
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following methodology section, as is the SF-36 Health Related Quality of Life questionnaire
(SF-36) and Pittsburgh Sleep Quality Index (PSQI).
H1: Perceived social functioning, as measured by the SF-36 subscale, will have a
significant negative relationship with depression scores.
H2: Overall health related quality of life, as measured by the SF-36, will have a
significant negative relationship with depression scores.
H3: Quality of sleep, as measured by the PSQI, will have a significant positive
relationship with depression scores, as in this measure, higher scores are equivalent to a poorer
quality of sleep.
H4: Length of time on dialysis will have a significant positive relationship with
depression scores.
H5: Age will have a significant negative relationship with depression scores.
H6: ESRD participants will score significantly differently from healthy controls on
measures of depression, social functioning, health related quality of life, and sleep quality.

11

CHAPTER III
METHODOLOGY

Participants
A sample of ESRD participants was recruited between November, 2012, and February,
2014, as part of a larger study (Tumlin, Harris, & Whitson, 2012) by a local kidney research
institute (Southeastern Renal Research Institute, SERRI) in Chattanooga, Tennessee. Recruited
participants were tested based on their availability, willingness to participate, and various
inclusion and exclusion criteria. The full list of inclusion and exclusion criteria is included in
Appendix A. Fifteen participants were recruited and qualified for testing during the study period;
ten participants (66.7%) gave informed consent and completed the study. Two participants were
excluded from the analysis on any model that included length of time on dialysis due to missing
data, therefore the simple regression and multiple regression models that included length of time
on dialysis were analyzed with only 8 participants. Demographic and medical data were
collected after participants consented to this study, while all other participant data was collected
at a single visit at the SERRI clinic prior to further tests included in the larger study (Tumlin et
al., 2012) to ensure testing fatigue did not play a role in participants’ responses. Five healthy
(non-kidney disease) controls, matched on age, gender, and race, were recruited from a
community sample to compare the kidney disease sample to the healthy sample on depression,
social functioning, health related quality of life, and sleep quality.
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Measures
Demographics
Demographic and medical data for ESRD participants included age, gender, race, and
length of time on dialysis. Of the ten kidney disease participants, eight were male and two were
female, four were Caucasian and six were African American. The ESRD sample had a mean age
of 56.6 (SD = 12.3) ranging from 36 to 73, and the mean time on dialysis was 75.5 months (SD =
97.8) with a range of 3.2 to 251.4. The median time on dialysis was 29.9 months, which may be
a more informative measure of central tendency due to the small sample size in this study. Of the
five healthy control participants, four were male and one was female, four were Caucasian and
one was African American. The mean age of the group was 54.4 (+/- 11.8) ranging from 42 to
70.

Center for Epidemiologic Studies Depression Scale, Revised Version
The Center for Epidemiologic Studies Depression Scale, Revised Version (CESD-R) is
used to measure depression as defined by the American Psychiatric Association’s Diagnostic and
Statistical Manual (DSM-IV) (Eaton, Smith, Ybarra, Muntaner, & Tien, 2004). The scale
consists of 20 questions and measures depression symptoms on a Likert scale of 0 to 3 responses
for all 20 questions, where 0 corresponds to the lowest level of depressive symptoms and 3 to the
highest level of depression symptoms. A patient’s depression score is obtained by simply taking
the sum of all responses for a possible score of 0 to 60. The diagnostic cut-off for exhibiting
clinical depression symptoms is 16, with varying levels of diagnosis (mild, moderate, severe) for
those scoring above the cutoff. For the purposes of this study, the overall score from 0 to 60 for
each participant was used in the analyses to represent depression level. Reliability and validity
13

analyses for this scale have demonstrated high reliability with a Chronbach’s α of .928 and high
convergent and divergent validity (Eaton et al., 2004; Van Dam & Earleywine, 2011).

Short Form – 36 Health Related Quality of Life Questionnaire
The Short Form-36 Health Related Quality of Life Questionnaire (SF-36) is a measure of
quality of life relating to health issues, particularly measuring mental and physical components
(Ware & Sherbourne, 1992). The scale consists of 36 questions that assess eight subscales,
including social functioning, and two main components of mental and physical health. All
questions use a Likert scale, with each question varying in the range of responses (0-3, 0-5, 0-6).
Scoring of the SF-36 for each component and subscale is achieved by converting the raw score to
a percentage score, where a score of 100 represents the highest possible level of functioning and
0 represents the lowest possible level of functioning. For the purposes of this study, the social
functioning percentage score and the mean of all subscale percentage scores are used in analysis
to represent perceived social functioning and overall quality of life, respectively. Reliability and
validity estimates of the social functioning subscale and the questionnaire overall both show a
Chronbach’s α of .85, and high convergent and discriminant validity (McHorney, Ware, Lu, &
Sherbourne, 1994) .

Pittsburgh Sleep Quality Index
The Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire used to assess
sleep quality and disturbances over the month prior to the subject taking the questionnaire
(Buysse, Reynolds, Monk, Berman, & Kupfer, 1989). The questionnaire consists of nine
questions, some of which are free quantitative responses about sleep time and latency, and others
14

on a Likert Scale from 0 to 3. The scale can be separated into seven components, or used as an
overall measure that is equal to the sum of each component score. Component scores are
computed on a 0 to 3 scale, while the overall score has a range from 0 to 21, where an overall
score of 5 or greater indicates “poor sleep.” For the purposes of this study, the overall score from
0 to 21 for each participant is used in the analyses to represent sleep quality. It is important, for
interpretive purposes, to be mindful that a higher score indicates worse sleep quality for the
PSQI. Reliability and validity analyses conducted by the creators of the questionnaire revealed
strong reliability with an overall Chronbach’s α of .83, and significant convergent validity
correlations (Buysse et al., 1989).

Procedure
Participants were recruited at the SERRI clinic during a routine visit. After consenting,
kidney disease participants were scheduled for an appointment at SERRI at a later date for data
collection. Upon arrival at SERRI on the day of the appointment, participants were given a
questionnaire packet including the PSQI, SF-36, and CESD-R in that order. After completing the
packet, the participant’s involvement in this particular study was complete and they were free to
continue with the procedures of the larger study (Tumlin et al., 2012). If participants completed
the larger study, they were given $100 for their participation. Controls were recruited based on
age, gender, and race match with a kidney disease participant and availability in the greater
Chattanooga, Tennessee area. All healthy control data were collected in a single visit at The
University of Tennessee at Chattanooga. Controls were not incentivized for their participation in
the study. All data from ESRD participants and controls were entered into an encrypted
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Statistical Package for Social Sciences file for analysis. All individuals involved in the collection
or analysis of the data were HIPAA certified in the protection of human rights.

Statistical Analysis
IBM’s SPSS version 21 for Macintosh (IBM Corporation, 2012) was used for all of the
analyses in the study. First, an independent samples t-test was conducted to test for differences
between the healthy and kidney disease samples on age and measures of social functioning,
overall quality of life, sleep quality and depression. Age was tested here because not all ESRD
participants were matched with a healthy control. The t-test was used to test for any significant
difference in age between the control and kidney disease participants. Next, simple regressions
for each variable included in the study were run for the kidney disease group. These regressions
tested each factor’s relationship to depression scores. Finally, multivariate regression models
were used to determine if any combination of variables added significantly to the prediction of
depression scores in this sample. These models were compared to simple regression models to
assess the uniqueness of each predictor while the other variables were held constant.

16

CHAPTER IV
RESULTS

Findings
An independent samples t-test analysis was conducted first to determine if there was a
difference between the kidney disease sample and the healthy sample on measures of social
functioning, health related quality of life, sleep quality, and age. The results of analyses
comparing the groups are shown in Table 4.1. It is important to note that there was no significant
difference between the groups in age. These results indicate that age should not confound the
other variables included in the analysis. Results of the analysis also showed that kidney disease
participants differed significantly from the healthy control participants on measures of social
functioning, overall quality of life, and sleep quality (p < .05). Depression levels between the two
groups were marginally significant (p = .075).
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Table 4.1
Independent Samples T-Test Results Between Kidney Disease and Control Group
Factor
Age
Depression
Social Functioning
Overall Quality of Life
Sleep Quality

Group
Healthy
Kidney Disease
Healthy
Kidney Disease
Healthy
Kidney Disease
Healthy
Kidney Disease
Healthy
Kidney Disease

Mean
54.4
56.6
5.2
15.8
95.0
62.5
82.1
51.6
4.5
11.8

SD
11.8
12.3
4.0
1.4
14.5
19.9
3.3
11.8
11.2
27.0

t

p-value

-.331

.746

-1.938

.075

3.284

.010

3.019

.033

-3.529

.006

Before the regression analysis, each variable was assessed for normality to determine if
any transformations to the data were necessary. All tests of skewness and kurtosis indicated no
need for transformations. Normal probability plots for each variable are shown in Appendix E.
For the kidney disease group, the relationship between each of the variables and
depression was analyzed using SPSS’s linear regression procedure. A univariate regression was
conducted for each variable with depression. The results of these analyses are reported in Table
4.2. The individual analyses showed both social functioning (p = .012) and overall quality of life
(p = .007) to be significantly negatively related to depression scores. Age (p = .051) was found to
have a marginally significant negative relationship, while sleep quality (p = .744) and length of
time on dialysis (p = .193) were not significant.
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Table 4.2
Univariate Regression Analysis with Depression Results for Kidney Disease Participants
Factor

Pearson r

p-value

t

p-value

Social Functioning

-.755

.006

-3.252

.012

Overall Quality of
Life

-.783

.004

-3.564

.007

Sleep Quality

.119

.372

.338

.744

Length of Time
on Dialysis

-.514

.096

-1.468

.193

Age

-.630

.025

-2.294

.051

Next, multivariate analyses were conducted to determine if any combination of variables
served as a stronger predictor than any individual variable alone. Using SPSS’s linear regression
procedure, a series of models were created to assess all combinations of the variables. Each
model was compared on significance of the regression model, multiple r-square, and r-square
change values to determine if the model added significantly to the previous model. Using this
technique, 20 models were assessed, 7 of which were significant at a two-tailed p-value of less
than .05. It was discovered that the model including social functioning, sleep quality, and age
significantly predicted depression scores (p = .007) and accounted for the greatest amount of
sample variance in the depression scores (r2 = .852, adjusted-r2 = .778) of all models. In this
model, social functioning (t = -3.939, p = .008) and age (t = -2.685, p = .036) were significantly
negatively related to depression scores, while sleep quality was marginally significant and
positively related to depression scores (t = 2.429, p = .051).
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Correlations of each variable are shown in Table 4.3. A model including the significant
predictors from the univariate analysis (Social functioning, overall quality of life, age) was not
significant, most likely due to multicollinearity (high correlation between variables). In a case of
multicollinearity, the variable with the highest simple r is considered to have a stronger
relationship. Therefore, if only one measure is available, the health related quality of life is the
better measure in this study. In an additional note about the data analyses, sleep quality was not a
significant predictor when used alone, however when controlling for two of the other variables
(social functioning and age) it was. The variables that strengthen sleep quality’s relationship with
depression are called suppressor variables. With the relationship being positive, this finding
indicates that when social functioning and age are equal, those who have low sleep quality
(higher PSQI score) have high levels of depression.
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Table 4.3
Simple Pearson r Correlations of Variables

Depression

Social
Functioning

Quality of
Life

Sleep
Quality

Time on
Dialysis

Age

Depression

1

-.749

-.774

.308

-.514

-.569

Social
Functioning

-

1

.907

-.026

.461

.225

Quality of
Life

-

-

1

-.218

.280

.245

Sleep
Quality

-

-

-

1

.026

.103

Time on
Dialysis

-

-

-

-

1

.382

Age

-

-

-

-

-

1

Summary of Hypothesis Testing
H1: Perceived social functioning, as measured by the SF-36 subscale, was expected to
have a significant negative relationship with depression scores. This hypothesis was supported
by the data analyses. In both univariate and multivariate regression models, high levels of
perceived social functioning were significantly related to lower depression scores in the sample.
H2: Overall health related quality of life, as measured by the SF-36, was expected to
have a significant negative relationship with depression scores. This hypothesis was supported
by the data analysis. Similar to social functioning, in both univariate and multivariate regression
models, high levels of overall quality of life were significantly related to lower depression
scores.
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H3: Quality of sleep, as measured by the PSQI, was expected to have a significant
negative relationship with depression scores. This hypothesis was partially supported by the data
analysis. Quality of sleep was only significantly related to depression scores when its suppressor
variables were included in a multivariate analysis. Social functioning, overall quality of life, as
well as age acted as suppressor variables for sleep quality. When these factors were held
constant, better quality of sleep was significantly related to lower depression scores.
H4: Length of time on dialysis was expected to have a significant positive relationship
with depression scores. This hypothesis was not supported by the data analysis. In both
univariate and multivariate regression models, length of time on dialysis was not significantly
related to depression scores.
H5: Age was expected to have a significant negative relationship with depression scores.
This hypothesis was supported by the data analysis. Although marginally significant (p = .051)
in the univariate regression analysis, the multivariate analyses showed age to have a significant,
negative relationship with depression scores, when social functioning and sleep quality were held
constant.
H6: ESRD participants were expected to score significantly differently from the healthy
controls on measures of depression, social functioning, health related quality of life, and sleep
quality. The t-test analysis confirmed that in all measures except depression, the ESRD
participants were significantly different from healthy controls (p < .05). In the measure of
depression, ESRD participants scored only marginally significantly differently (p = .075) than
healthy controls. In all measures, the ESRD participants scored worse than control participants
(i.e. higher depression scores than healthy controls, lower social functioning scores than healthy
controls, etc.)
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CHAPTER V
DISCUSSION

Interpretation of Findings
The results of the t-test suggest some important factors that should be addressed when
interpreting the findings of this study. While the ESRD group was marginally significantly
different from the healthy group on the measure of depression, the mean of the ESRD group was
only 15.8. The literature on the measure indicates that any score greater than or equal to 16 is
considered showing clinical depression symptoms (Eaton et al., 2004). Therefore, while the
ESRD participants may be different from the healthy control group, it is important to note that
they are not showing very high symptoms of depression, as would be expected from the
literature. This sample of ESRD participants may reflect a group of “super patients” that feel
well enough to participate in a research study and may not be very representative of the ESRD
population as a whole.
The results of the univariate regression analysis showed social functioning, overall
quality of life, and age (marginally) to be significantly related to depression scores. For all of
these factors the relationship to depression was negative, meaning that as social functioning,
overall quality of life, or age increased, depression levels decreased. While many of these
findings were expected based on the literature, the negative relationship between age and
depression is interesting because the relationship is possibly counterintuitive compared to other
studies on age effects in other populations. These results are consistent however with Laudanski
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et al.’s (2013) findings that younger ESRD patients use more emotional preoccupation to cope
with the disease than older ESRD patients. These results suggest it is possible that younger adults
are more affected by the disease due to their life circumstances (i.e. taking care of their family)
compared to older adults who may be less relied on by family members.
The results of the length of time on dialysis analyses were not significant; however, these
results may warrant more consideration than other non-significant findings. The inclusion criteria
listed in Appendix A, require the patients to be on dialysis for greater than three months. This
criterion may have limited the sample to exclude a crucial period of time at first diagnosis where
having ESRD can be the most impactful mentally. The length of time on dialysis may not be as
much of a factor after being on dialysis for greater than three months, however, time since
diagnosis may have an entirely different impact. The subjective response to being diagnosed may
play a larger role in depression of ESRD patients, due to the substantial impact the disease
treatment can have on one’s life.
Multivariate analyses were used to determine the relationship between two or more
variables while holding other variables in the analysis constant. This allows us to assess if the
relationship is due to the variable, or other factors influencing the relationship. It also allows us
to examine the relationship of a combination of the variables, to determine if a combination of
variables has a stronger relationship to depression over any variable alone. The results of these
analyses found the combination of social functioning, sleep quality, and age to account for the
greatest amount of variability in the depression scores of the sample. The adjusted multiple rsquare of .778 estimates what percentage of the differences that these variables would account
for if applied to the population based on the number of predictors, and sample size. The high
adjusted multiple r-square is particularly important in this study because of the unusually small
24

sample size, and suggests that these three factors could provide a focus for caretakers of ESRD
patients. However, as mentioned previously, these results should be interpreted with caution due
to the type of participants that were recruited for this study.

Limitations
The most outstanding limitation in the present study is the sample size of 10 for kidney
disease participants and 5 for healthy controls. Sample sizes did not meet the projected amount
during the data collection period due to withdrawals of consent, missed appointments, and
difficulty of recruitment. As part of a larger study, recruitment and appointment scheduling
involved many groups and individuals to be available, and required the participants to show up
for their scheduled appointment. Along with a small sample size, the unequal distribution of
males (n = 8) to females (n = 2) as well as the missing data on length of time on dialysis for two
participants, made the analysis of gender as a factor unfeasible and any analysis that included
length of time on dialysis was restricted to 8 participants, further shrinking an already small
sample size. Furthermore, the sample used in this study was made up of ESRD patients that were
willing and able to participate in the study. This factor may have influenced the results of the
analysis as these ESRD patients might be considered “super subjects” that are healthier than
other ESRD patients, and who may not be representative of the population as a whole
consequently.
Another limitation of the present study involves the measures that were used. The SF-36
health related quality of life scale, and subscale measure of social functioning may not be the
strongest measure of quality of life and social functioning in the ESRD population according to a
review by Glover et al. (2011) comparing the content validity of six different quality of life
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measures across various studies on quality of life in the ESRD population. Out of 378 articles
reviewed, it was found that the SF-36 measure was the most commonly used, however, the
KDQOL-SF had the highest content validity of all six measures reviewed. This disease specific
measure may provide a more valid and accurate assessment of quality of life, compared to a
generic measure, in ESRD patients specifically. However, while a disease specific measure will
most likely be more valid in studying the ESRD population, there are some circumstances where
a generic measure may also be appropriate, most notably in a comparison to other chronic
disease populations. Disease specific measures do not allow for these comparisons across
populations, therefore, in these circumstances a generic measure may be more appropriate. In
these instances, the review by Glover et al. (2011) found the World Health Organization Quality
of Life assessment, abbreviated version (WHOQOL-BREF) to be a more appropriate measure in
respect to content validity compared to the other general health related quality of life
questionnaires reviewed, including the SF-36. The authors suggest that the widespread use of the
SF-36 in this population is the result of it being used commonly in studies of other chronic
diseases and that its data is easy to compare across different groups. However, the authors
caution the use of this measurement because it does not measure all aspects of quality of life of
the ESRD population, and suggest the use of the WHOQO-BREF as it is similarly short, and
easy to administer, while also providing a measure of the aspects of quality of life that the SF-36
misses (Glover et al., 2011). This review provides a claim that future studies should be used to
strengthen the body of research on alternative quality of life measures for a better comparison
between the many different measures.
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Recommendations for Future Studies
Future studies should examine these factors in a larger sample size, using a disease
specific measure of social functioning instead of a generic measure and subscales of quality of
life. Although not all factors were significant, a larger sample size with more accurate measures
could find vastly different results, while also providing more data on other quality of life
measures in the ESRD population. These results could be used in comparison to other studies
using a generic quality of life measure to determine if a disease specific measure provides more
accurate results in studies on this population.
Furthermore, longitudinal studies examining the impact of these same factors included in
the present study over a period of time would help determine which of these events was the
original problem. With correlational data, no inference can be made about which factor caused
which. Longitudinal analyses could answer some important questions, such as, “Does depression
cause poor sleep quality? Or does poor sleep quality cause depression?” With answers to these
questions, caretaking strategies could better focus on the original problem, rather than treating
the symptoms.
Additionally, objective measures of social support, quality of life, sleep quality, and
depression should be considered in future studies. All measures included in the present study
were self-report. The discrepancy between perceived support or quality of life and actual support
or quality of life as measured by family members and friends could provide more insight as to
what treatments may be most effective. For example, increasing the presence of available social
support may not be an effective treatment option if the patient claims to have a different level of
support than what family members and friends report. The problem in these cases may be a
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perception issue, rather than an actual level of support issue, which should be an important factor
to consider when deciding treatment options for these patients.
Other studies could involve testing the effectiveness of interventions based on these
results to determine if there are any effective augmentations to current depression treatments for
kidney disease patients suffering from depression symptoms. An example of these studies
include testing the effectiveness of interventions to increase sleep quality in kidney disease
patients, a goal of the larger study (Tumlin et al., 2012) from which the present study was
conducted. With the increasing life expectancy of these patients, it is crucial to conduct these
studies to determine the safest and most efficient way to lowering depression prevalence and
increasing quality of life in this population. Future studies looking at similar constructs could
also be expanded to other chronic diseases with similar statistics as ESRD populations to
determine if these factors are disease specific or can be generalized to other populations.
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APPENDIX A
INCLUSION/EXCLUSION CRITERIA
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Inclusion Criteria:
1) Patient age > 18 and <85 years of age
2) Patients with CKD or ESRD with eGFR < 30 mls/min
3) If receiving hemodialysis, patients must be on treatment > 3 months
4) Normal healthy controls must be without a known history of CKD and be willing to
have formal PSG test and plasma melatonin measurements

Exclusion Criteria:
1) Patients receiving outpatient hemodialysis for < 3 months
2) Patients with estimated GFR by Cockcroft Gault > 30 mls/min
3) Patients receiving beta blocker therapy within one month of randomization
4) Patients receiving Nifedipine therapy within one month randomization
5) Patients on peritoneal dialysis
6) Patient with chronic home oxygen supplementation
7) Patients receiving chronic home CPAP therapy
8) Patients actively receiving outpatient sleep medications
9) Patients with diabetic gastroparesis unresponsive to medication
10) Patients with known pregnancy or unwilling to use contraception during the course of
the study
11) Patients with a functioning renal allograft
12) Patient currently receiving long-term immunosuppressive therapy. Patients receiving
low dose prednisone (10mg or less per day) will not be excluded from this trial
13) Unable to give informed consent
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APPENDIX B
SF-36 HEALTH RELATED QUALITY OF LIFE QUESTIONNAIRE (SF-36)
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SF-36

Name_____________________________________
Date______________________________________
Moderator__________________________________

1) In general, would you say your health is: (circle one)
a) Excellent
b) Very good
c) Good
d) Fair
e) Poor
2) Compared to one year ago, how would you rate your health in general now? (circle one)
a) Much better now than one year ago
b) Somewhat better now than one year ago
c) About the same
d) Somewhat worse now than one year ago
e) Much worse now than one year ago
Place a check mark or “X” in the appropriate box. Only select one for each question.
In a typical day, does your health now limit you
in these activities? If so, how much?
3. Vigorous activities, such as running, lifting
heavy objects, participating in strenuous sports
4. Moderate activities, such as moving a table,
pushing a vacuum cleaner, bowling, or playing
golf
5. Lifting or carrying groceries
6. Climbing several flights of stairs
7. Climbing one flight of stairs
8. Bending, kneeling, or stooping
9. Walking more than one mile
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Yes,
Limited a
Lot

Yes, Limited
a Little

No, Not
Limited at All

Place a check mark or “X” in the appropriate box. Only select one for each question.
In a typical day, does your health now limit
Yes, Limited Yes, Limited
No, Not
you in these activities? If so, how much?
a Lot
a Little
Limited at All
10. Walking several blocks
11. Walking one block
12. Bathing or dressing yourself

Place a check mark or “X” in the appropriate box. Only select one for each question.
During the past 4 weeks, have you had any of the following problems with
your work or other regular daily activities as a result of your physical
health?

Yes

No

13. Cut down on the amount of time you spent on work other activities
14. Accomplished less than you would like
15. Were limited in the kind of work or other activities
16. Had difficulty performing the work or other activities (for example, it
took extra effort)

Place a check mark or “X” in the appropriate box. Only select one for each question.
During the past 4 weeks, have you had any of the following problems with
your work or other regular daily activities as a result of any emotional
problems (such as feeling depressed or anxious)?
17. Cut down on the amount of time you spent on work other activities
18. Accomplished less than you would like
19. Were limited in the kind of work or other activities
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Yes

No

20. During the past 4 weeks, to what extent has your physical health or emotional problems
interfered with your normal social activities with family, friends, neighbors, or groups?
(Circle one)
a) Not at all
b) Slightly
c) Moderately
d) Quite a bit
e) Extremely
21. How much bodily pain have you had during the past 4 weeks? (Circle one)
a) None
b) Very mild
c) Mild
d) Moderate
e) Severe
f) Very severe
22. During the past 4 weeks, how much pain interfered with your normal work (including both
work outside the home and house work)? (Circle one)
a) Not at all
b) A little bit
c) Moderately
d) Quite a bit
e) Extremely
Place a check mark or “X” in the appropriate box. Only select one for each question.
During the past 4 weeks…

All of
Most of
the Time the Time

23. Did you feel full of pep?
24. Have you been a nervous
person?
25. Have you felt so down in
the dumps that nothing could
cheer you up?
26. Have you felt calm and
peaceful?
27. Did you have a lot of
energy?
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A Good
A Little
Some of
None of
Bit of
Bit of
the Time
the Time
the Time
the Time

Place a check mark or “X” in the appropriate box. Only select one for each question.
A Good
A Little
All of
Most of
Some of
None of
During the past 4 weeks…
Bit of
Bit of
the Time the Time
the Time
the Time
the Time
the Time
28. Have you felt
downhearted and blue?
29. Did you feel worn out?
30. Have you been a happy
person?
31. Did you feel tired?

32. During the past 4 weeks, how much of the time has your physical health or emotional
problems interfered with your social activities (like visiting with friends, relatives, etc.)?
(Circle one)
a) All of the time
b) Most of the time
c) Some of the time
d) A little of the time
e) None of the time
Place a check mark or “X” in the appropriate box. Only select one for each question.
How true or false is each of the following
statements for you?

Definitely Mostly
True
True

33. I seem to get sick a little easier than
other people
34. I am as healthy as anybody I know
35. I except my health to get worse
36. My health is excellent
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Don’t
Know

Mostly Definitely
False
False

APPENDIX C
CENTER FOR EPIDEMIOLOGIC STUDIES DEPRESSION SCALE,
REVISED VERSION (CESD-R)
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CESD-R
Name_____________________________________
Date______________________________________
Moderator__________________________________
Place a check mark or “X” in the appropriate box. Only select one for each question.
Last Week
Below is a list of the ways you might
Nearly
Not at all
have felt or behaved. Please check
every
the boxes to tell me how often you
or Less
day
for 2
1-2
days
3-4
days
5-7
days
have felt this way in the past week or
than 1
weeks
so.
day
1) My appetite was poor.
2) I could not shake the blues.
3) I had trouble keeping my
mind on what I was doing.
4) I felt depressed.
5) My sleep was restless.
6) I felt sad.
7) I could not get going.
8) Nothing made me happy.
9) I felt like a bad person.
10) I lost interest in my usual
activities.
11) I slept much more than
usual.
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12) I felt that I was moving too
slowly.
13) I felt fidgety.
14) I wished I were dead.
Place a check mark or “X” in the appropriate box. Only select one for each question.
Last Week
Below is a list of the ways you might
Nearly
Not at all
have felt or behaved. Please check
every
the boxes to tell me how often you
or Less
day
for 2
1-2
days
3-4
days
5-7
days
have felt this way in the past week or
than 1
weeks
so.
day
15) I wanted to hurt myself.
16) I was tired all the time.
17) I did not like myself.
18) I lost a lot of weight
without trying to.
19) I had a lot of trouble
getting to sleep.
20) I could not focus on the
important things.
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APPENDIX D
PITTSBURGH SLEEP QUALITY INDEX (PSQI)
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PSQI
Number__________________
Date_____________________
During the past month,
1. When have you usually gone to bed (what time)? _________________
2. How long (in minutes) has it taken you to fall asleep each night? ________________
3. When have you usually gotten up in the morning? ____________________
4. How many hours of actual sleep do you get at night? (This may be different than the
number of hours you spend in bed) _________________
5. During the past month, how often have you had
trouble sleeping because you…

Not
during
the past
month

Less
than
once a
week

Once or
twice a
week

Three or
more
time a
week

Very
Good

Fairly
Good

Fairly
Bad

Very
Bad

a. Cannot get to sleep within 30 minutes
b. Wake up in the middle of the night or early
morning
c. Have to get up to use the bathroom
d. Cannot breathe comfortably
e. Cough or snore loud
f. Feel too cold
g. Feel too hot
h. Have bad dreams
i. Have pain
j. Other reason(s), please describe, including how
often you have trouble sleeping because of this
reason(s):
6. During the past month, how often have you taken
medicine (prescribed or “over the counter”) to help
you sleep?
7. During the past month, how often have you had
trouble staying awake while driving, eating meals, or
engaging in social activity
8. During the past month, how much of a problem has it
been for you to keep your enthusiasm to get things
done?

9. During the past month, how would you rate your
sleep quality overall?
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APPENDIX E
NORMAL PROBABILITY PLOTS OF VARIABLES
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Social Functioning

Overall Quality of Life
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Sleep Quality

Time on Dialysis
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Age
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APPENDIX F
INFORMED CONSENT DOCUMENT
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Informed Consent Form
While we hope that you will complete the attached study, your participation is voluntary.
You may elect not to participate at any time. In addition, if you do not feel comfortable
answering any of the questions you may leave that question blank and continue with the
rest of the study. The information you provide will be anonymous and we do not ask you to
identify yourself in any way. Boredom and Nasal Dryness are the only risks associated with
your participation in this project. You will not receive any direct benefit from participating
in the study.
This first part of the study will ask you to respond to questions about sleeping, general
health, and recent feeling or behaviors. The second part of the study will ask you to identify
smells located on scratch and sniff booklets. The third part will ask you to respond whether
or not you detected an odor in a tube. The last thing the study asks you to do is fill out a
demographic page. The demographic information will ask about age, gender, ethnicity,
occupation, education, smoker vs. non-smoker, history with health illnesses, and any
medications being taken. These questions will help us to interpret the results of the rest of
the study.
We expect that it will take approximately 1 hour to participate in this study.
Remember, this is an anonymous survey, so please do not write your name anywhere other
than this page.
You may also request a copy of this form for your records.
Who to Contact
If you have any questions or would like to obtain a report of this research study when the
results have been completed, please contact Dr. Nicky Ozbek (423-425-4262), Department
of Psychology, University of Tennessee at Chattanooga. This survey is being conducted as
part of a Student Senior Research Project. This project meets the requirements for
approval by the UTC IRB and contact can be made to the UTC IRB through Director Lindsay
Pardue (423-425-4443) and Chair Dr. Bart Weathington (423-425-4289).
Thank you for participating in our research!
Name (Print) _____________________________________________ Date________________
Signature ________________________________________________ Date________________
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APPENDIX G
IRB APPROVAL DOCUMENTS
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MEMORANDUM

TO:

Dr. Nicky Ozbek
Dr. James Tumlin

IRB # 12-196

FROM:

Lindsay Pardue, Director of Research Integrity
Dr Bart Weathington, IRB Committee Chair

DATE:

November 28, 2012

SUBJECT:

IRB Application # 12-196: Olfactory Sensitivity and Depression in Dialysis
Patients

The IRB Committee Chair has reviewed and approved your application and assigned you the IRB number
listed above. You must include the following approval statement on research materials seen by
participants and used in research reports:
The Institutional Review Board of the University of Tennessee at Chattanooga (FWA00004149) has
approved this research project # 12-196.
Since your project has been deemed exempt, there is no further action needed on this proposal unless
there is a significant change in the project that would require a new review. Changes that affect risk to
human subjects would necessitate a new application to the IRB committee immediately.
Please remember to contact the IRB Committee immediately and submit a new project proposal for
review if significant changes occur in your research design or in any instruments used in conducting the
study. You should also contact the IRB Committee immediately if you encounter any adverse effects
during your project that pose a risk to your subjects.
For any additional information, please consult our web page http://www.utc.edu/irb or email us at:
instrb@utc.edu .
Best wishes for a successful research project.
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MEMORANDUM

TO:

Dr. Nicky Ozbek

IRB # 12-196

FROM:

Lindsay Pardue, Director of Research Integrity
Dr. Bart Weathington, IRB Committee Chair

DATE:

January 10, 2013

SUBJECT:

IRB #:12-196: Olfactory Sensitivity and Depression in Dialysis Patients

The Institutional Review Board has reviewed and approved the following changes for the IRB project
listed below:


We would like to add the odor threshold test and the scratch and sniff cards for the odorant
vanilla. Neither the WUTC odor threshold test nor the vanilla scratch and sniff cards had been
available at the time of the original submission of the Melatonin grant profile. The addition of
these tests instruments requires the patient consent form to include their administration in the
consent. Approval of this modification has been obtained from the IRB of the UT College of
Medicine scientific review board. A copy of the approval letter is attached.

You must include the following approval statement on research materials seen by participants and used
in research reports:
The Institutional Review Board of the University of Tennessee at Chattanooga (FWA00004149) has
approved this research project # 12-196.
Please remember that you must complete a Certification for Changes, Annual Review, or Project
Termination/Completion Form when the project is completed or provide an annual report if the project
takes over one year to complete. The IRB Committee will make every effort to remind you prior to your
anniversary date; however, it is your responsibility to ensure that this additional step is satisfied.
Please remember to contact the IRB Committee immediately and submit a new project proposal for
review if significant changes occur in your research design or in any instruments used in conducting the
study. You should also contact the IRB Committee immediately if you encounter any adverse effects
during your project that pose a risk to your subjects.
For any additional information, please consult our web page http://www.utc.edu/irb or email
instrb@utc.edu
Best wishes for a successful research project.
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